Evotec SE ADR Cash Flow Conversion Efficiency
Evotec SE ADR cash flow conversion efficiency. Based on the latest financial reports, Evotec SE ADR (EVO) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.18 Million) by net assets ($700.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Evotec SE ADR (2003–2025)
Cash flow conversion efficiency of Evotec SE ADR from 2003 to 2025. This chart illustrates how Evotec SE ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Evotec SE ADR share price for real-time trading data and today's change.
Evotec SE ADR Cash Flow Conversion Ratio Explained
Evotec SE ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Evotec SE ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ADR ranked by their cash flow conversion efficiency. Also see Evotec SE ADR (EVO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hannstar Display Corp
TW:6116
|
0.012x |
|
ABOUT YOU Holding AG
F:YOU
|
-0.403x |
|
Yuanta Futures Co Ltd
TWO:6023
|
0.087x |
|
Lotte Corp
KO:004990
|
0.052x |
|
Cymbria Corporation
TO:CYB
|
0.001x |
|
Cibus Nordic Real Estate AB (publ)
ST:CIBUS
|
0.041x |
|
El Puerto de Liverpool S.A.B. de C.V
MX:LIVEPOLC-1
|
0.012x |
|
Shinkong Synthetic Fiber Corp
TW:1409
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Evotec SE ADR (2003–2025)
The table below shows the annual cash flow conversion efficiency of Evotec SE ADR from 2003 to 2025. Review Evotec SE ADR free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $813.36 Million | $-9.06 Million | -0.011x | -158.26% |
| 2024-12-31 | $952.52 Million | $18.22 Million | 0.019x | -36.90% |
| 2023-12-31 | $1.12 Billion | $33.95 Million | 0.030x | -82.51% |
| 2022-12-31 | $1.19 Billion | $205.81 Million | 0.173x | +95.39% |
| 2021-12-31 | $1.38 Billion | $122.24 Million | 0.089x | +75.86% |
| 2020-12-31 | $886.41 Million | $44.72 Million | 0.050x | -36.01% |
| 2019-12-31 | $535.47 Million | $42.22 Million | 0.079x | -78.56% |
| 2018-12-31 | $424.88 Million | $156.24 Million | 0.368x | +1026.64% |
| 2017-12-31 | $331.75 Million | $10.83 Million | 0.033x | -89.63% |
| 2016-12-31 | $213.94 Million | $67.36 Million | 0.315x | +276.39% |
| 2015-12-31 | $187.09 Million | $15.65 Million | 0.084x | +448.94% |
| 2014-12-31 | $158.38 Million | $-3.80 Million | -0.024x | -157.25% |
| 2013-12-31 | $158.97 Million | $6.66 Million | 0.042x | -46.57% |
| 2012-12-31 | $152.55 Million | $11.96 Million | 0.078x | +13.75% |
| 2011-12-31 | $147.25 Million | $10.15 Million | 0.069x | +916.62% |
| 2010-12-31 | $132.64 Million | $899.00K | 0.007x | +103.46% |
| 2009-12-31 | $111.49 Million | $-21.85 Million | -0.196x | +28.84% |
| 2008-12-31 | $149.86 Million | $-41.28 Million | -0.275x | -48.33% |
| 2007-12-31 | $170.55 Million | $-31.67 Million | -0.186x | -176.14% |
| 2006-12-31 | $137.18 Million | $-9.22 Million | -0.067x | -367.85% |
| 2005-12-31 | $148.67 Million | $-2.14 Million | -0.014x | +95.23% |
| 2004-12-31 | $61.73 Million | $-18.60 Million | -0.301x | +22.58% |
| 2003-12-31 | $36.03 Million | $-14.02 Million | -0.389x | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more